Actavis has launched a portfolio of generic specialty injectable medications to be marketed to hospitals in the U.S. Actavis will begin marketing approximately 20 injectable products across a number of therapeutic areas in the U.S., including generic versions of oncology drugs Gemzar, Taxotere, Campostar and Zometa. Actavis also has a specialty injectable pipeline, with approximately 20 new filings under FDA review and more than 50 additional projects in development.   Many of the generic specia...